initial tick bite [4, 5] . The second and third stages may occur without the clinical manifestations of the earlier stage.
Epidemiologic studies of Lyme disease have been difficult to conduct, in part because erythema migrans is the only unique clinical manifestation of Lyme disease and, consequently, accurate case ascertainment can be difficult to establish based on clinical criteria alone for persons with cardiac, neurologic, or arthritic manifestations, especially without antecedent erythema migrans. Indirect immunofluorescence assays (IFA) and enzyme-linked immunosorbent assays (ELISA) now exist for detecting antibodies to Borrelia burgdorferi [12, 13] . Because these tests have a sensitivity approaching 100 percent during the secondary and tertiary stages of Lyme disease, stages when the disease can be the most difficult to diagnose, more complete case ascertainment is now possible [13, 14] . The specificities of the IFA and ELISA tests are high: of ten healthy controls and 30 persons with rheumatoid arthritis, systemic lupus erythematosus, or infectious mononucleosis who were tested by ELISA [13] , and of 40 healthy controls and 51 persons with unknown febrile illness tested by both ELISA and IFA [14] , none were positive for antibodies to Borrelia burgdorferi. Although cross-reactivity occurs with tick-borne relapsing fever, louse-borne relapsing fever, syphilis, yaws, and Rocky Mountain spotted fever [15] , these diseases are usually easily distinguished from Lyme disease on the basis of clinical or epidemiologic findings.
From July 1984 to March 1986, we studied Lyme disease in Connecticut using a laboratory-based surveillance system. Our objectives were to determine the frequencies of the most common clinical manifestations, the descriptive epidemiology of Lyme disease in Connecticut, especially its geographic distribution, and the sensitivity of the serologic test during early Lyme disease as determined by a surveillance system. The findings of this study are the subject of this report.
METHODS

Case Ascertainment and Reporting
Serologic testing for Lyme disease has been available to patients of Connecticut physicians since 1983 from the Connecticut Agricultural Experiment Station. In the spring of 1984, three announcements from the Connecticut State Department of Health Services were mailed to all general internists, internal medicine subspecialists, general pediatricians, pediatric subspecialists, family practitioners, and neurologists licensed to practice in Connecticut to inform them about Lyme disease and to spread the word further about the availability of free serologic testing for all suspected Lyme disease cases. Physicians were required to complete a case report form with all specimens submitted for testing from July 1, 1984, to March 1, 1986 . In addition, physicians were asked to report voluntarily suspected cases of Lyme disease from whom serologic testing was not sought. The case report form included information about the patient's demographic characteristics, detailed clinical history, and history of tick bite. Information about the patient's race, number and size of erythema migrans lesions, constitutional symptoms, and specific joint involvement, and the specialty of the referring physician was obtained only for persons reported in 1984.
Only Connecticut residents with onset of illness in 1984 or 1985 were included in the analyses reported here. To meet the case definition, a resident had to have either erythema migrans or to have neurologic [8, 9] , cardiac [10, 11] , or arthritic [4, 5] manifestations consistent with Lyme disease and at least one positive serologic test result. Persons with erythema migrans who had reported neurologic, cardiac, or arthritic symptoms and a negative serologic test result were considered to have erythema migrans as their only Lyme disease manifestation. This distinction was primarily made to minimize misclassifying arthralgia as arthritis. Arthralgia frequently occurs in early Lyme disease when the serology is often negative, whereas arthritis, which occurs later, is almost always accompanied by a positive serology. Persons with a positive serologic test but without erythema migrans, and without cardiac, neurologic, or arthritic manifestations were not counted as cases.
Although information submitted on the case report form was not systematically validated, the medical charts of 72 persons with erythema migrans and 29 persons with arthritis reported as part of this surveillance study in 1984 were reviewed in 1987. Ninety-four percent of patients with erythema migrans and 93 percent of patients with arthritis had sufficient information recorded in the medical chart to confirm these diagnoses [16] .
Long-term changes in Lyme disease incidence were assessed by comparing 1977 incidences for residents of nine towns west of the Connecticut River (Chester, Clinton, Deep River, Essex, Haddam, Killingworth, Madison, Old Saybrook, and Westbrook) [17] and three towns east of the Connecticut River (East Haddam, Lyme, and Old Lyme) [17] to the 1985 incidences found in this study. The study conducted in 1977 utilized an active surveillance system where all physicians in the study communities were contacted in person and by telephone. Although the case definition used in the 1977 study was similar to that used in 1984-1985, serologic testing was not available in 1977 to confirm the diagnosis of Lyme disease in those with neurologic, cardiac, or arthritic manifestations. Misclassification of patients with arthritis in 1977 was minimized, however, because patients were required to have laboratory and clinical evidence that should have excluded other causes of arthritis.
Serological Assay
All serum samples were tested by IFA or ELISA with a polyvalent conjugate using methods described elsewhere [15, [18] [19] [20] . Serum samples received before July 1985 were tested by IFA; sera received later were analyzed by ELISA. In a preliminary study of 139 patients with erythema migrans reported in 1984, both tests had 95 percent concordance when identical paired sera were tested [20] . For (16 percent) . The remainder were reported by specialists in rheumatology (9 percent), dermatology (3 percent), infectious disease (2 percent), neurology (1 percent), or other fields (7 percent).
Epidemiologic Features
In 1985, the first complete year of reporting, 66 percent (408) of 619 case-persons with known month of onset had onsets in June, July, and August (Fig. 1) . When comparisons in Lyme disease incidence were limited to those with onset of symptoms from July to December, time periods during both reporting years when serologic testing was equally available, a 24 percent increase was observed from 1984 (397) to 1985 (492).
Estimated Lyme disease incidence for all Connecticut residents was 22/ 100,000 in 1985. Because the geographic location where the tick bite occurred was often dnknown, town-specific incidences were computed by town of residence. Lyme disease was sharply demarcated in geographic distribution. In 1985, Lyme disease incidence for Connecticut towns ranged from zero to 1,156/100,000, and every town with an incidence >300/100,000 population was located within 40 kilometers of another town where Lyme disease was not reported (Fig. 2) . High-incidence towns were located in southeastern Connecticut and in the lower Connecticut River Valley. Almost half (48 percent) of towns with an incidence of 1-49/100,000 had only one case-resident. Compared to 1977 data, the 1985 incidence increased by 129 percent (280/100,000 to 650/100,000) in three towns east of the Connecticut River, and by 453 percent (13/100,000 to 73/100,000) in eight towns west of the River.
Fifty-one percent (585/1,149) of persons with Lyme disease were male. All but one of the 372 case-persons reported in 1984 whose race was specified were white. Age-specific Lyme disease incidence was tabulated by five-year age groups for those with symptom onset in 1985. Incidence ranged from 11/100,000 for persons aged 20 to 24 years to 39/100,000 for those aged five to nine years (Fig 3) .
Clinical Features
Overall, 911 (83 percent) of those with Lyme disease had erythema migrans, 252 (24 percent) had arthritis, 84 (8 percent) had neurologic manifestations, and 22 (2 percent) had cardiac involvement (Table 1 ). Data about the number and size of erythema migrans skin lesions were available for 285 persons reported in 1984: 31 percent (89/285) had two or more erythema migrans lesions; the median size of the largest lesion was 10 centimeters, with a range of 1 to 45 centimeters. Information about specific joint involvement was available for 44 of 49 persons with arthritis reported during 1984. Affected joints were the knee (89 percent), hip (9 percent), shoulder (9 percent), ankle (7 percent), and elbow (2 percent).
The distribution of some symptoms was age-dependent. Among those with Lyme disease, persons <20 years old were almost twice as likely to have arthritis as those .20 years old (Table 2 ). There was, however, no corresponding increase in frequency of neurologic or cardiac manifestations in case-persons <20 years old ( Of those with serologic tests, 37 percent (1,117) had two specimens and 3 percent (86) had three specimens submitted for testing. Specimens from 1,447 persons were analyzed by IFA, and specimens from 1,579 persons were analyzed by ELISA.
Neither the IFA nor the ELISA was sensitive during the early stages of disease. The positivity rate for the first serum specimen for those with erythema migrans was only 30 percent by IFA and 24 percent by ELISA (Table 3 ). The sensitivity of both the IFA and the ELISA improved if the serum sample was drawn -21 days after the onset of illness. DISCUSSION
Our data indicate that Lyme disease is spreading geographically in Connecticut. In 1977, epidemiologic studies in Connecticut showed that Lyme disease occurred almost exclusively in towns located near the shoreline and east of the Connecticut River [15, 23] , areas where the tick vector, I. dammini, was abundant [24] . By 1983, entomologic and serologic studies suggested that the geographic distributions of I. dammini and human B. burgdorferi infections had extended northward in the Connecticut River Valley and into northeastern Connecticut [25, 26] . By 1985, Lyme disease was endemic in nearly all towns in southeastern Connecticut; four of these towns were located >25 kilometers from the shoreline and had incidences >300 per 100,000 population.
Our surveillance data also suggest that the incidence of Lyme disease is increasing in Connecticut. From 1984 to 1985, the incidence increased by 24 did not change over both reporting years, suggesting that reporting patterns did not change overall. Nevertheless, the observed annual rate of increase is consistent with the 129 percent to 453 percent increases in incidence observed from 1977 to 1985 in southeastern Connecticut. It is doubtful that the magnitude of this increase could be accounted for by different surveillance methodologies or case definitions. In fact, the 1977 study may have had greater case ascertainment because physicians were telephoned to report cases [17] . Anecdotal reports received by us from physicians with long-standing practices in Lyme and surrounding communities also suggest that Lyme disease markedly increased in incidence from 1977 to 1985.
Although the observed Lyme disease incidence was considerable in some towns, our surveillance system probably underestimated the actual incidence for several reasons: (I) the system was laboratory-based, so that many persons with erythema migrans, a unique clinical marker of Lyme disease, may not have had serologic testing; (2) persons with stage one disease who had atypical skin rashes or nonspecific symptoms would not have been defined as cases, regardless of the serologic test results; (3) the diagnosis of Lyme disease may not have been considered for those with atypical presentations; and (4) sera from some Connecticut residents may have been tested at Yale University. Although the actual number tested at Yale was unknown, a record review of all patients tested there from July to December 1984 found only seven additional Connecticut residents who would have met the case definition for this study.
Our data also indicate that there is age-specific variation in Lyme disease incidence and clinical response to Borrelia burgdorferi infection. Children five to 14 years of age had the highest Lyme disease incidence. It is unknown if they had the greatest exposure to ticks, were more likely to develop symptoms after infection, or were simply more likely to be reported. A previous serologic study of a defined island population suggested that adults were less likely to develop symptoms after infection than children [27] . We also found that persons with Lyme disease who were <20 years of age were more likely to have arthritis as the first manifestation of Lyme disease than were persons .20 years of age. This finding is supported by the longitudinal study of an island population that also found that children were more likely to present with arthritis alone [27] .
Serologic tests for Lyme disease have generally been reported to have low or moderate sensitivity during stage-one Lyme disease [12] [13] [14] 28] . In a preliminary study of 139 patients with erythema migrans, ELISA and IFA tests had comparable sensitivities, regardless of whether class-specific IgM or polyvalent conjugates were used [20] . In our study, the ELISA with a polyvalent conjugate had an overall sensitivity of only 24 percent. This low value could be due to delayed immune response or to previous antibiotic treatment [28] . In view of the low sensitivities of serologic tests during early Lyme disease, it is particularly important for physicians to re-evaluate clinical data when antibodies are not detected. If necessary, a second or third serum sample should be obtained to monitor a rise in antibody levels. Serologic testing, however, remains a valuable diagnostic tool for patients with secondary or tertiary stages of Lyme disease [13] .
